GlassScriptPhysician profile
Douglas L Yeager
NPI 1588632467
$1,252.95
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $293 · 2021: $334 · 2022: $239.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $192.27 | 2019-2022 | |
| Pfizer INC. | $165.67 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $122.45 | 2019-2020 | |
| Amarin Pharma, INC. | $120.89 | 2019-2021 | |
| Amgen INC. | $108.93 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.27 | 2020-2022 | |
| Lilly USA, LLC | $83.80 | 2020-2022 | |
| Hikma Pharmaceuticals USA | $65.65 | 2019-2022 | |
| Abbvie INC. | $51.98 | 2020-2021 | |
| Novo Nordisk INC | $38.22 | 2020-2021 | |
| Glaxosmithkline, LLC. | $35.88 | 2021-2022 | |
| Eisai INC. | $30.96 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $23.55 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $23.18 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.44 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $17.38 | 2020 | |
| Genentech USA, INC. | $16.77 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.31 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.21 | 2021 | |
| Allergan, INC. | $11.14 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Yeager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.